These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 482136)

  • 1. [Dipyridamole pharmacokinetics in liver diseases].
    Markiewicz A; Semenowicz K; Korczyńska J
    Pol Arch Med Wewn; 1979 Jun; 61(6):463-70. PubMed ID: 482136
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronopharmacokinetics of dipyridamole.
    Markiewicz A; Semenowicz K; Korczynska J; Czachowska A
    Int J Clin Pharmacol Biopharm; 1979 May; 17(5):222-4. PubMed ID: 468446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathways and tissue distribution of dipyridamole (Persantin).
    Mellinger TJ; Bohorfoush JG
    Arch Int Pharmacodyn Ther; 1965 Aug; 156(2):380-8. PubMed ID: 5895707
    [No Abstract]   [Full Text] [Related]  

  • 4. Does a rhythmicity of serum concentrations and urinary excretion of dipyridamole exist during long-term treatment?
    Markiewicz A; Semenowicz K
    Pol J Pharmacol Pharm; 1980; 32(3):289-95. PubMed ID: 7197020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipyridamole disposition after chronic administration: effect of aspirin.
    Rosenfeld J; Buchanan MR; Reilly PA; Turpie AG
    Thromb Res Suppl; 1983; 4():137-43. PubMed ID: 6579707
    [No Abstract]   [Full Text] [Related]  

  • 6. The bioavailability of three dipyridamole products.
    Markiewicz A; Hartleb M; Boldys H
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):499-501. PubMed ID: 6642785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in dogs.
    Stracciari GL; Malvisi J; Anfossi P; Fregnan GB
    Arch Int Pharmacodyn Ther; 1989; 300():7-13. PubMed ID: 2619427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bioavailability of two dipyridamole formulations.
    Markiewicz A; Semenowicz K; Szczyrba E; Kocek B
    Pol J Pharmacol Pharm; 1978; 30(5):605-9. PubMed ID: 582068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison.
    Terhaag B; Donath F; Le Petit G; Feller K
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):298-302. PubMed ID: 3733279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of the aspirin-dipyridamole combination in man and animal on their respective blood kinetics].
    Decourt S; Hazard MC; Beyne P; Paris J; Fayard JM; Flouvat B
    Therapie; 1983; 38(3):255-63. PubMed ID: 6612662
    [No Abstract]   [Full Text] [Related]  

  • 11. Persantine bioavailability problems.
    Lehmann CR; Locke K; Pierson WP; Shaffer PJ; Hall W
    Clin Pharm; 1984; 3(1):14-5. PubMed ID: 6697671
    [No Abstract]   [Full Text] [Related]  

  • 12. [The bioavailability of dipyridamole in the form of liposomes].
    Stozek T; Krówczyński L
    Pharmazie; 1986 Sep; 41(9):645-7. PubMed ID: 3797455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of the individual factor and the plasma-organ concentration relationship in rats treated with dipyridamol. I. The heart].
    Jiménez-Castellanos R; Fernández R; Faulí C
    Boll Chim Farm; 1984 Jul; 123(7):322-9. PubMed ID: 6518090
    [No Abstract]   [Full Text] [Related]  

  • 14. Thermodynamic differences between the binding interaction of nitrobenzylthioinosine and dipyridamole with the nucleoside transport system of human erythrocytes.
    Clanachan AS; Hammond JR
    Proc West Pharmacol Soc; 1983; 26():251-3. PubMed ID: 6889349
    [No Abstract]   [Full Text] [Related]  

  • 15. Spectrofluorimetric assessment of plasma dipyridamole stability: sample storage for multicenter clinical trials?
    Serebruany V; Pokov I; Hanley D
    Thromb Res; 2008; 123(1):184-6. PubMed ID: 18691742
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of liver diseases on pharmacokinetics of drugs].
    Lazowski J; Rewerski W
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):95-9. PubMed ID: 2216955
    [No Abstract]   [Full Text] [Related]  

  • 17. Absorption and activity of 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d) pyrimidine (RA8) following enteric administration.
    Kadatz R; Beisenherz G
    Arch Int Pharmacodyn Ther; 1965 Dec; 158(2):389-402. PubMed ID: 5868589
    [No Abstract]   [Full Text] [Related]  

  • 18. Dipyridamole bioavailability in subjects with reduced gastric acidity.
    Derendorf H; VanderMaelen CP; Brickl RS; MacGregor TR; Eisert W
    J Clin Pharmacol; 2005 Jul; 45(7):845-50. PubMed ID: 15951475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific determination of dipyridamole in serum by high-performance liquid chromatography.
    Pedersen AK
    J Chromatogr; 1979 Jan; 162(1):98-103. PubMed ID: 762215
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of cytarabine uptake and toxicity by dipyridamole.
    King ME; Naporn A; Young B; Howell SB
    Cancer Treat Rep; 1984 Feb; 68(2):361-6. PubMed ID: 6697325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.